Mounjaro and weight loss: experiences and results in Sweden 2026

March 21

Mounjaro weight loss is increasingly discussed on Swedish forums and in social media, and interest has exploded since the drug became more widely available in Europe in 2024-2025. Mounjaro contains the active substance tirzepatide, developed by Eli Lilly, and represents a new generation of weight loss drugs that affect not one but two hormonal signaling pathways simultaneously. The results from clinical studies have surpassed anything seen before in pharmacological weight treatment — but the reality for Swedish users does not always look like the studies suggest. Here we review mounjaro results, dosage for weight loss, realistic time frames and what the experience actually shows.

How does Mounjaro work for weight loss — tirzepatid’s dual mechanism?

Tirzepatid is a so-called dual GIP/GLP-1 receptor agonist. While older weight loss drugs such as semaglutide (Ozempic/Wegovy) only activate the GLP-1 receptor, tirzepatide stimulates both GLP-1 and GIP (glucose-dependent insulinotropic peptide) at the same time. This dual activation explains why, in direct comparison, Mounjaro provides greater weight loss than semaglutide.

GLP-1 activation slows gastric emptying, reduces appetite via signals to the hypothalamus, and improves insulin sensitivity. GIP activation adds a fat-burning component that GLP-1 alone does not provide — GIP receptors are found in adipose tissue and influence how the body stores and mobilizes fat. The combination means that users experience both markedly reduced hunger and a change in how the body handles excess energy at the cellular level.

In the SURMOUNT-1 study (published in the New England Journal of Medicine in 2022), participants on the highest dose of tirzepatide (15 mg) lost an average of 22.5% of their body weight over 72 weeks. The control group lost 2.4%. The difference of 20 percentage points is the largest documented in any randomized drug weight loss trial. Read more about tirzepatid as a breakthrough in weight treatment for a deeper review of the research.

Mounjaro results — how much weight do you realistically lose?

The study results paint a picture, but the reality outside of controlled clinical trials often looks different. In studies with strict follow-up, dietary advice and regular visits, participants achieve maximum results. In real clinical practice — without a dietitian, without weekly checks — weight loss is typically 30-50% lower.

|Parameter|Study results (SURMOUNT-1)|Real clinical practice (estimation)|

|Average weight loss at 72 yrs|22.5% (15mg)| 12–16 % |

|Proportion losing >10%| 89 % | 55–70 % |

|Proportion losing >20%| 57 % | 20–35 % |

|Time to plateau|60–72 weeks|40–52 weeks|

The difference is due to several factors. Participants in studies are carefully selected, motivated and receive regular professional follow-up. In reality, patients manage side effects on their own, skip doses when they feel unwell, and often lack the structured support offered by the study protocol. Despite this, the results in clinical practice are impressive compared to older weight loss drugs — Orlistat, for example, gives 3-5% weight loss and even semaglutide is lower in real data.

Mounjaro before and after pictures abound on social media and often give a skewed picture. The most dramatic transformations are shared the most, while those who lose 8-10% rarely post. A realistic expectation for an average Swedish patient with BMI 32–35 who follows the escalation schedule and makes reasonable dietary adjustments: 12–18 kg during the first year. It’s a life-changing weight loss for most — but it’s not the 30+ pounds that the most viral posts show.

Mounjaro dosage weight loss — escalation and what happens at each step

Tirzepatid is dosed as a subcutaneous injection once weekly. The escalation schedule is designed to minimize gastrointestinal side effects and is the same regardless of indication.

What does the dosage ladder look like in practice?

Treatment always starts at 2.5 mg per week during the first four weeks. This starting dose rarely results in noticeable weight loss — the purpose is to allow the body to adapt to the substance and minimize nausea. After four weeks, the dose is increased to 5 mg, where most people begin to notice a decrease in appetite and the first kilos disappear.

Escalation then continues in steps of 2.5 mg every four weeks: from 5 mg to 7.5 mg, then to 10 mg, 12.5 mg and finally 15 mg. Not everyone needs to reach the maximum dose — if the weight loss is satisfactory at 10 mg and the side effects are manageable, there is no reason to escalate further. Many doctors in Sweden stop at 10–12.5 mg if the patient reaches his goals.

Why do some users skip dosage steps?

Some users report that they on their own increased the dose faster than recommended, motivated by impatience or stagnation. This strategy almost always results in more severe nausea, diarrhea and sometimes vomiting forcing them to go back to a lower dose. The escalation schedule exists for a reason — the GLP-1 receptors in the GI tract need time to adjust. Respecting the time frames provides better long-term tolerance and reduces the risk of having to stop treatment completely due to intolerable side effects.

Mounjaro experiences — what do Swedish users report?

The experiences of Swedish users largely agree with international reports, but there are nuances worth highlighting. The recurring themes in Swedish patient groups and forums:

• The change in appetite is described as the most dramatic effect — not only reduced hunger but a changed relationship with food. Thoughts of food diminish, and portions are halved without effort of will. Several describe it as “food consumption stops being a project”.

• Nausea during escalation affects an estimated 60-70% to some degree, but varies widely. Some manage the entire escalation without problems, while others vomit regularly when increasing the dose from 5 to 7.5 mg. Eating slowly, avoiding fatty foods and taking the injection in the evening seem to alleviate symptoms according to experience reports.

• Paradoxically enough, energy levels improve in most people — despite reduced calorie intake, many report increased energy and better sleep already after 4–6 weeks of treatment, likely linked to improved insulin sensitivity and reduced inflammation.

• Availability in Sweden has been problematic during 2025–2026. Periodic supply shortages, varying subsidy decisions between regions and price changes have meant that treatment is perceived as unsafe to begin. The cost without subsidy is around SEK 3,500–5,000 per month.

The overall impression is that Mounjaro delivers results that surpass previous drugs, but that the side effects during the escalation require patience and that availability in Sweden is still uneven. Detailed information about price, side effects and practical dosage can be found in our guide on Mounjaro tirzepatid in Sweden.

Mounjaro before and after — what happens when treatment ends?

The question that is rarely discussed in marketing but that every patient should understand: what happens to the weight after treatment? The SURMOUNT-4 study investigated exactly this, and the results were unequivocal — participants who discontinued tirzepatide after 36 weeks regained an average of 14 percentage points of their weight loss over the following 52 weeks, while those who continued treatment maintained their new weight.

Weight regain is due to the fact that the hormonal mechanisms that Mounjaro affects — appetite regulation, gastric emptying, insulin signaling — return to their original state when the substance leaves the body. Hunger returns, portions gradually increase and the body’s energy balance shifts towards weight gain. This mechanism applies to all GLP-1-based drugs, not just tirzepatide.

In practice, this means that Mounjaro should be considered a long-term treatment rather than a course with a start and end. Patients planning to quit need a transition strategy — established dietary habits, regular physical activity, and possibly a lower maintenance dose — to minimize relapse. Expecting that the weight will remain on its own after the end of treatment is not supported by the available data. The conversation with your doctor should include a plan for what happens after — not just during — treatment.

.entry-content